第一作者单位：[1]Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai, Peoples R China[2]Cent South Univ, Affiliated Canc Hosp, Hunan Canc Hosp, Dept Thorac Med,Xiangya Sch Med, Changsha, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China[4]China Med Univ, Shengjing Hosp, Dept Oncol, Shenyang, Peoples R China[5]Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China[6]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China
推荐引用方式(GB/T 7714)：
Ni JianJiao,Wu Lin,Chu Qian,et al.Sintilimab, SBRT and GM-CSF for metastatic NSCLC: A prospective, multicenter, phase II trial[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Ni, JianJiao,Wu, Lin,Chu, Qian,Han, Chengbo,Ai, Xinghao...&Zhu, Zhengfei.(2023).Sintilimab, SBRT and GM-CSF for metastatic NSCLC: A prospective, multicenter, phase II trial.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Ni, JianJiao,et al."Sintilimab, SBRT and GM-CSF for metastatic NSCLC: A prospective, multicenter, phase II trial".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学